Document is current

Article History

Received: 5 May 2023

Accepted: 7 May 2023

First Online: 17 May 2023

Declarations

:

: All animal procedures were carried out in accordance with institutional and European guidelines and approved by the UCLouvain Ethical Committee for Animal Welfare (Reference 2018/UCL/MD/38). Human post-mortem brain tissue was collected in accordance with the applicable laws in Belgium (UZ Leuven) and Germany (Ulm). The recruitment protocols for the collection of human brains were approved by the ethical committees of UZ Leuven (Belgium; S-59292, S-52971) and the University of Ulm (Germany; 54/08). This study was approved by the UZ-Leuven ethical committee (Belgium; S-64378).

: Not applicable.

: DRT received speaker honorary or travel reimbursement from UCB (Brussels, Belgium) and Biogen (USA), and collaborated with Novartis Pharma AG (Basel, Switzerland), Probiodrug (Halle (Saale), Germany), GE Healthcare (Amersham, UK), and Janssen Pharmaceutical Companies (Beerse, Belgium). RV’s institution has clinical trial agreements (RV as Principal Investigator) with Alector, Biogen, Denali, J&J, Prevail, UCB, Roche and Wave. RV’s institution has consultancy agreements for DSMB membership (RV) with AC Immune and Novartis. CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk, and Dr. Wilmar Schwabe GmbH &Co. KG, funding for travel and speaker honoraria from Biogen, Roche diagnostics AG, Novartis, Medical Tribune Verlagsgesellschaft GmbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V. and Dr. Wilmar Schwabe GmbH &Co. KG and has received research support from Roche diagnostics AG. The other authors have no relevant financial or non-financial interests to disclose.